Delivery system for budesonide based on lipid-DNALiu, Y., Bos, I. S. T., Oenema, T. A., Meurs, H., Maarsingh, H. & Hirsch, A. K. H., Sep-2018, In : European Journal of Pharmaceutics and Biopharmaceutics. 130, p. 123-127 5 p.
Research output: Contribution to journal › Article › Academic › peer-review
Budesonide is a hydrophobic glucocorticoid with high anti-inflammatory activity for the treatment of asthma, inflammatory bowel disease and rheumatoid arthritis. A micellar drug-delivery system based on lipid-DNA may provide a strategy to maximize its drug efficacy and reduce adverse effects. In this work, we report the use of lipid-DNAA (UU11mer), featuring two hydrophobic alkyl chains and forming micelles at a comparatively low critical micelle concentration, to render budesonide water-soluble with a high loading capacity (LC). The inhibition of interleukin-8 (IL-8) release shows that the new delivery system retains the inhibitory activity in cell based assays. In conclusion, this research provides a novel approach to formulate and administer budesonide in a non-invasive manner, which dramatically improves its water-solubility while retaining its bioavailability.
|Number of pages||5|
|Journal||European Journal of Pharmaceutics and Biopharmaceutics|
|Publication status||Published - Sep-2018|
- Drug delivery, Anti-inflammatory, Budesonide, Lipid-DNA, Solubility, AIRWAY SMOOTH-MUSCLE, DRUG-DELIVERY, RHEUMATOID-ARTHRITIS, ULCERATIVE-COLITIS, POLYMERIC MICELLES, CROHNS-DISEASE, ASTHMA, THERAPY, PHARMACOKINETICS, CORTICOSTEROIDS